Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908619 | 0.92 | AR (0.44) | XDHNPBWR1MCHR1 | |
| SCHEMBL14207203 | 0.84 | HSP90AA1 (0.41) | ALDH1A1CACNA1H | |
| SCHEMBL24908614 | 0.82 | CYP11B1 (0.42) | XDHCACNA1H | |
| SCHEMBL24908515 | 0.80 | CACNA1H (0.39) | KDM4EALDH1A1CACNA1H | |
| SCHEMBL22831651 | 0.79 | XDH (0.47) | XDHKDM4EUSP2ALDH1A1 | |
| SCHEMBL24908613 | 0.75 | NOTUM (0.41) | CACNA1H | |
| SCHEMBL11150870 | 0.74 | ALDH1A1 (0.58) | KDM4EUSP2ALDH1A1CACNA1H | |
| SCHEMBL7865160 | 0.73 | XDH (0.58) | XDH | |
| SCHEMBL2609437 | 0.73 | MAPKAPK2 (0.48) | KDM4EALDH1A1NPBWR1MCHR1 | |
| SCHEMBL24908424 | 0.73 | GRM5 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | XDH 1567/4885KDM4E 2710/4885USP2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.